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Abstract
Background When multiple treatments are available,
network meta-analysis can synthesize evidence and rank
their relative profile in terms of effectiveness and/or safety.
We applied this approach to the safety of subcutaneous
biologicals used in the treatment of moderate to severe
psoriasis.
Methods Our literature search covered the articles pub-
lished from January 2000 to September 2014 and was
restricted to randomized controlled trials. The agents eli-
gible for our analysis were subcutaneous biological drugs
used in patients with moderate to severe psoriasis. A net-
work meta-analysis was conducted using the Bayesian
model. The analysis was aimed to compare the safety of
these treatments based on 95 % credible intervals and to
consequently generate a ranking in safety across the
treatments. Two safety end-points were considered: any
serious adverse events (AE) and any infectious AE. Risk
difference was the outcome measure. The analysis esti-
mated 95 % credible intervals for all direct and indirect
comparisons as well as the ranking histogram across the
treatments which was determined according to model-
based probabilistic analysis.
Results Our literature search selected a total of 13 ran-
domized controlled trials of which three evaluated ada-
limumab, five ustekinumab (45 and 90 mg), four
etanercept (both high-dose and low-dose) and one high-
dose etanercept and ustekinumab (45 and 90 mg). For both
end-points of any serious AE and any infectious AE, the
Bayesian analysis showed no significant difference in all
indirect head-to-head comparisons between active agents.
For the end-point of any serious AE, the ranking was us-
tekinumab 45 mg and ustekinumab 90 mg (at the same
rank), followed by placebo and by adalimumab and high-
dose etanercept (at the same rank). For any infectious AE,
the ranking was: low-dose etanercept, placebo, us-
tekinumab 45 mg and ustekinumab 90 mg, adalimumab
and high-dose etanercept.
Conclusion Our analysis synthesized the current evidence
on the safety of subcutaneous biological treatments for
patients with moderate to severe psoriasis and was suc-
cessful in defining their respective rankings.
Introduction
In the area of biological drug treatments for patients with
psoriasis, several comparative studies have already dealt
with the effectiveness of these agents [1–5], but no such
studies have been conducted about their safety [6].
In the present study, we examined the data of compar-
ative safety in patients with moderate to severe psoriasis
obtained from randomized trials evaluating adalimumab,
ustekinumab and etanercept. We applied Bayesian network
meta-analysis to synthesize this information, determine the
statistical significance of differences between active treat-
ments, and rank the treatments according to safety end-
points.
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The clinical material for our analysis was derived from
published randomized trials in which adalimumab, us-
tekinumab or etanercept were used to treat patients with
moderate to severe psoriasis. Only dosages compatible
with the summary of product characteristics were consid-
ered. Two safety end-points (or adverse events, AE) were
evaluated: (a) any serious AE, and (b) any infectious AE.
Literature Search
The literature search, based on PubMed, covered the last
10 years. Only randomized controlled trials (RCTs)
(according to PubMed definitions) evaluating the safety of
adalimumab, ustekinumab and etanercept were eligible for
our analysis. The search terms ‘‘(ustekinumab OR ada-
limumab OR etanercept) AND safety’’ were used.
Data Synthesis and Analysis
We employed Bayesian network meta-analysis [7–9]. In
the field of direct and indirect comparisons, this ‘‘all-in-
one’’ approach is increasingly being used and can now be
considered the current standard. As compared with the
traditional frequentist approach [9], the Bayesian method
demonstrates one main advantage in that all treatments
included in the comparisons are incorporated into a single
model. In contrast, in most frequentist approaches (e.g. the
Bucher method [9]) there are as many separate analyses as
the number of comparisons being studied. Another
advantage of the Bayesian approach is that this technique
enables rank ordering of the treatments concerned. As
opposed to traditional confidence intervals adopted in
frequentist analysis, the Bayesian output reports credible
intervals, which can be directly interpreted as the proba-
bility of an event residing in the reported range.
The Bayesian analysis involves a formal combination of
a prior probability distribution that reflects a prior belief of
the possible values of the effect of interest, and the like-
lihood distribution of the effect based on the observed data,
to obtain a posterior distribution. In the absence of real
data, prior probabilities are assigned by using vague, flat or
non-informative priors (that are generally small numbers
between 0 and 3).
The Bayesian model adopted for our analysis [7–9] has
been developed by the NICE Support Unit (UK) and is
available as fixed-effect model and random-effect model
(WINBUGS software). Both employ a random sequence of
chains, called the Markov chain Monte Carlo simulation.
Each chain must be run for a length of time sufficient to
allow model convergence (burn-in) before estimating
posterior probabilities. We run the fixed-effect model using
the binary outcome of how many AE (any serious AE and
any infectious AE) in each arm of each study occurred.
Randomization within each study was preserved by spec-
ifying each arm in each study separately, thus accounting
for the effect of the comparator.
We planned to run both the fixed-effect model and the
random-effect model and to choose the best one for our
purposes on the basis of the deviance information criterion
(which is a sort of goodness-of-fit test implemented in the
WINBUGS software). Results were presented as risk dif-
ference (RD). We accounted for heterogeneity among
studies by applying meta-regression techniques and by
consequently generating an index of heterogeneity.
Both direct comparisons and indirect comparisons were
considered. The values of RD were associated with their
respective 2.5–97.5 % credible interval (i.e. 95 % credible
interval), that reflects a formal level of statistical signifi-
cance at 5 %. Direct comparisons are those for which at
least a single clinical trial was available while indirect
comparisons are those for which no ‘real’ trial has been
done. Finally, as a sensitivity analyses, we changed the
initial values from which each Markov chain Monte Carlo
simulation began, as is customary in the Bayesian frame-
work [7–9].
Recent advances in computing power and the develop-
ment of sophisticated software have greatly facilitated the
use of Bayesian statistics. All of our analyses were con-
ducted by using the software package WinBUGS 1.4.3
(Cambridge, UK) in combination with the meta-analysis
code developed by the National Institute for Health and
Care Excellence [10].
Results
Literature Search and Identification of Included Studies
Our literature search, which is summarized in Fig. S1,
extracted a total of 192 citations. For a further scrutiny of
the material eligible for our analysis, we examined the full
text of 20 articles. After examining these papers, we
selected a total of 13 RCTs that met our inclusion criteria.
Of these studies, three evaluated adalimumab [11–13], five
ustekinumab (45 and 90 mg) [14–18], four low-dose and
high-dose etanercept [19–22] and one high-dose etanercept
and ustekinumab (45 and 90 mg) [23]. All of these trials
adopted a double-blind design and analysed the safety of
these treatments in terms of any serious AE or any infec-
tious AE.
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Bayesian Network Meta-Analysis
Tables S1 and S2 illustrate for each drug the raw data of
any serious AE and of any infectious AE end-point inci-
dence, respectively, derived from the RCTs included in our
analysis [11–23].
All of these trials used placebo as common comparator,
with the exception of the study by Griffiths et al. [23]. in
which the end-point of any serious AE was compared
between high-dose etanercept and ustekinumab (45 and
90 mg).
For both end-points of any serious AE and any infec-
tious AE, the Bayesian analysis (fixed-effect model)
showed no significant difference in all indirect head-to-
head comparisons between active agents; as shown in
Tables S3 and S4, all of the 95 % credible intervals for all
indirect comparisons between active agents (six for any
serious AE and ten for any infectious AE) included zero.
The results obtained from the Bayesian random-effect
model were nearly identical, but the goodness of fit was
slightly worse (data not shown).
Figure 1 shows our results concerning the end-point of
any serious AE calculated according to the Bayesian model
in relation to all possible direct and indirect comparisons;
the left panel shows the Forest plot, while the right panel
shows the rankogram (in which the five treatments are
compared with one another according to their safety).
Table S3 shows the numerical values of risk difference
(with 95 % credible intervals).
Figure 2 shows the results concerning the end-point of
any infectious AE calculated according to the Bayesian
model in relation to all possible direct and indirect com-
parisons. Also in this case, the left panel shows the Forest
plot, while the right panel shows the rankogram. Table S4
shows the numerical values of risk difference (with 95 %
credible intervals).
For the end-point of any serious AE, the overall ranking
(from highest safety to lowest safety) was ustekinumab
45 mg and (at the same rank) ustekinumab 90 mg, placebo,
adalimumab and (at the same rank) high-dose etanercept.
With regard to the end-point of any infectious AE, the
overall ranking was: low-dose etanercept, placebo,
Fig. 1 End-point of any serious AE. Left panel values of risk
difference (with 95 % credible intervals) calculated for all direct and
indirect comparisons according to the Bayesian fixed-effect model.
Right panel rankogram comparing the five treatments; rank 1
indicates lowest safety while rank 5 indicates highest safety
Ranking the Safety of Subcutaneous Biologicals in Psoriasis 25
ustekinumab 45 mg and ustekinumab 90 mg, adalimumab
and high-dose etanercept.
Discussion
Our results provided a synthesis of the safety data of
subcutaneous biological drugs available for the treatment
of moderate to severe psoriasis and was successful in
determining the statistical significance of differences
between active treatments and in defining their respective
rankings. In a context where five different subcutaneous
treatments are available and have in fact been tested in
RCTs, our comprehensive picture of current therapeutic
evidence can be of interest from several viewpoints.
The information on relative rankings (along with the
probabilistic analysis) represents—in our view—our most
interesting result. In particular, our findings concerning the
end-point of any serious AE suggest that ustekinumab at
both dosages ranked first and was close to the probabilistic
results observed with placebo. For the end-point of any
infectious AE, low-dose etanercept ranked better than the
other treatments; high-dose etanercept ranked last in this
analysis, but one should keep in mind that these indirect
comparisons between active agents did not reach the
threshold of statistical significance. It is well known that
Bayesian models provide a two-fold key for interpreting
the results: on the one hand, statistical testings resulting
from Bayesian models can be interpreted according to the
traditional keys of interpretation that are commonly
employed in frequentist analysis (e.g. the dichotomy
between significant and non-significant results); on the
other hand, the probabilistic analysis on which ranking
histograms are based provides another key for interpreting
the results in which the descriptive component tends to
prevail on the statistical component.
The strengths of our study included, in the first place, the
originality of the methodological approach inasmuch this is
the first ‘all-in-one’ Bayesian meta-analysis conducted on
this specific topic. Another advantage is represented by our
choice to evaluate all biologicals currently available for
subcutaneous use, without focusing the analysis on a single
agent (as in other published papers).
Our study had some limitations. Firstly, since we
adopted the end-point definitions employed in the original
studies, we cannot rule out that some differences existed in
Fig. 2 End-point of any infectious AE. Left panel values of risk
difference (with 95 % credible intervals) calculated for all direct and
indirect comparisons according to the Bayesian fixed-effect model.
Right panel rankogram comparing the six treatments; rank 1 indicates
lowest safety while rank 6 indicates highest safety
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these definitions. In particular, from an examination of
included studies, the definitions of any serious AE proved
to be quite consistent across the different clinical trials; in
contrast, there seemed to be more between-study hetero-
geneity in the definitions of any infectious AE. This is
confirmed by our finding that credible intervals were gen-
erally wider in Fig. 2 than in Fig. 1. Finally, another lim-
itation of our study is that further end-points other than
those examined in our analysis could be implicated in the
safety profile of these treatments (e.g. incidence of allergic
phenomena).
In conclusion, our results convey original information
that allows us to better interpret the safety profile of these
five agents. Overall, our findings indicate that the magni-
tude of the expected incidence of AE cannot represent the
main criterion for selecting a specific agent since these
differences tend to be small and lack statistical signifi-
cance. In the selection of a specific agent, other criteria
should therefore prevail, including the rapidity of effect
[6], the dosing schedule, and—last but not least—the cost.
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